HWP
ZNTL icon

Highline Wealth Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Highline Wealth Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,000
Closed -$6.75K – 1391
2025
Q4 		$6.75K Sell
5,000
-7,000
-58% -$10.2K ﹤0.01% 485
2025
Q3 		$18.1K Buy
12,000
+5,000
+71% +$7.5K ﹤0.01% 294
2025
Q2 		$8.12K Buy
+7,000
New +$9.23K ﹤0.01% 363

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Highline Wealth Partners's ZNTL Position: Q1 2026 in Review

Highline Wealth Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 5,000 shares — an estimated $6.75K sold.

Highline Wealth Partners first reported a position in ZNTL in Q2 2025 and held it in 3 quarters. The position peaked at $18.1K in Q3 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Highline Wealth Partners reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Highline Wealth Partners sold 5,000 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $6.75K.
  • Highline Wealth Partners first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Highline Wealth Partners's Zentalis Pharmaceuticals position peaked at $18.1K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Highline Wealth Partners's 13F filing for Q1 2026, filed 6 Apr 2026.